WalterHanelMD

Physician

Dr. Hanel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Start of enrollment: 2021 Sep 01
Active, not recruiting
Phase 1
Roles: Sponsor-Investigator, Principal Investigator, Contact

PubMed

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma.
Sayan Mullick Chowdhury, Subodh Bhatta, Timothy J Voorhees, Kaitlin Annunzio, David A Bond
Journal of Hematology & Oncology. 2025-01-05
2 citations
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
Narendranath Epperla, Ying Huang, Amanda F Cashen, John L Vaughn, Walter Hanel
Blood Advances. 2024-11-12
1 citations
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, Hyeongseon Jeon, Chelsea Peterson
Blood Advances. 2024-06-25

Abstracts/Posters

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Walter Hanel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Targeting Hypersumoylation in Mantle Cell Lymphoma
Walter Hanel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019